- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Johann Sebastian de Bono discusses the complexities of PARP inhibition in prostate cancer treatment. The presentation highlights concerns about widespread PARP inhibitor use without proper patient selection and raises awareness about potential long-term risks, while emphasizing the need for improved testing methods and careful cons...
|
- Details
- At the 2024 Advanced Prostate Cancer Consensus Conference (APCCC), Elena Castro provides a comprehensive overview of PARP inhibitor safety profiles in prostate cancer treatment. The presentation outlines specific management strategies while addressing the rare risk of myelodysplastic syndrome and acute myeloid leukemia, concluding that for patients with BRCA or HRR alterations, the benefits outwei...
|
- Details
- Oliver Sartor speaks with Louise Emmett about combination therapy approaches with lutetium-PSMA in prostate cancer. The discussion explores various combination strategies, including promising results from the ENZA-p trial combining lutetium-PSMA with enzalutamide, which shows notable response rates in first-line mCRPC. They examine multiple potential combination approaches, including hormonal ther...
|
- Details
- Andrea Miyahira speaks with Ayesha Shafi about a study on AR coactivators CBP/p300 in prostate cancer. The research reveals that CBP/p300 expression increases as prostate cancer progresses to castration-resistant stages, correlating with poor patient survival. Through various preclinical studies, Dr. Shafi demonstrates that CBP/p300 plays a crucial role in DNA repair, particularly in homologous re...
|
- Details
- Ursula Vogl discusses key prostate cancer highlights from ESMO 2024. The conversation explores three major trials across different disease stages: the PATCH trial evaluating transdermal estradiol versus LHRH analogs in non-metastatic disease, the ARANOTE trial examining darolutamide in metastatic hormone-sensitive prostate cancer, and the PEACE-3 trial investigating radium-223 plus enzalutamide in...
|
- Details
- Rashid Sayyid and Zachary Klaassen discuss the resurgence of radium-223 in treating metastatic castration-resistant prostate cancer (mCRPC), focusing on the PEACE-3 trial results. The conversation begins with an overview of radium-223's mechanism as a targeted alpha emitter and its historical efficacy in the ALSYMPCA trial, before exploring its underutilization despite FDA approval. The discussion...
|
- Details
- Wilbert Zwart joins Neeraj Agarwal to discuss research on epigenetic targeting in prostate cancer. The discussion examines histone markers in metastatic castration-resistant prostate cancer (mCRPC) patients to predict response to enzalutamide treatment. Using patient-derived xenografts and computational modeling, the research identifies HDAC3 as a key target and demonstrates synergistic effects wh...
|
- Details
- Evan Yu joins Zachary Klaassen to discuss the results of the ARROW trial. The study evaluates Iodine-131-LNTH-1095, a novel PSMA radioligand therapy, in combination with enzalutamide versus enzalutamide alone for metastatic castration-resistant prostate cancer patients who previously received abiraterone. While the trial meets its primary endpoint with significantly higher PSA decline rates in the...
|
- Details
- Bram De Laere discusses the ProBio trial, a platform study for metastatic prostate cancer. Dr. De Laere explains the trial's unique design, which uses circulating tumor DNA analysis to guide treatment decisions and evaluate multiple biomarker-therapy combinations simultaneously. The study demonstrates that AR pathway inhibitors generally outperform taxane-based chemotherapy in mCRPC patients, with...
|
- Details
- While most patients with prostate cancer are diagnosed with localized disease, a subset will develop metastatic disease, and subsequently castration-resistant prostate cancer (mCRPC), which remains incurable. Additionally, an increasing number of patients will present with de novo metastatic prostate cancer, known as metastatic castration-sensitive prostate cancer (mCSPC), and may progress to mCRP...
|
